Logo image of AGTC

APPLIED GENETIC TECHNOLOGIES (AGTC) Stock Fundamental Analysis

NASDAQ:AGTC - US03820J1007 - Common Stock

0.3936 USD
+0 (+1.23%)
Last: 11/30/2022, 8:18:22 PM
0.3936 USD
0 (0%)
After Hours: 11/30/2022, 8:18:22 PM
Fundamental Rating

1

Taking everything into account, AGTC scores 1 out of 10 in our fundamental rating. AGTC was compared to 542 industry peers in the Biotechnology industry. AGTC may be in some trouble as it scores bad on both profitability and health. AGTC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year AGTC has reported negative net income.
AGTC had a negative operating cash flow in the past year.
In the past 5 years AGTC always reported negative net income.
In the past 5 years AGTC always reported negative operating cash flow.
AGTC Yearly Net Income VS EBIT VS OCF VS FCFAGTC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 20M -20M 40M -40M 60M -60M

1.2 Ratios

AGTC has a worse Return On Assets (-122.50%) than 85.05% of its industry peers.
Industry RankSector Rank
ROA -122.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGTC Yearly ROA, ROE, ROICAGTC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 -50 -100 -150 -200

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AGTC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGTC Yearly Profit, Operating, Gross MarginsAGTC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

AGTC does not have a ROIC to compare to the WACC, probably because it is not profitable.
AGTC has more shares outstanding than it did 1 year ago.
AGTC has a worse debt/assets ratio than last year.
AGTC Yearly Shares OutstandingAGTC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M 40M 50M
AGTC Yearly Total Debt VS Total AssetsAGTC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -11.20, we must say that AGTC is in the distress zone and has some risk of bankruptcy.
AGTC has a Altman-Z score of -11.20. This is amonst the worse of the industry: AGTC underperforms 82.71% of its industry peers.
AGTC has a Debt/Equity ratio of 0.39. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of AGTC (0.39) is worse than 85.36% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Altman-Z -11.2
ROIC/WACCN/A
WACC11.71%
AGTC Yearly LT Debt VS Equity VS FCFAGTC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 1.40 indicates that AGTC should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.40, AGTC is doing worse than 88.94% of the companies in the same industry.
A Quick Ratio of 1.40 indicates that AGTC should not have too much problems paying its short term obligations.
The Quick ratio of AGTC (1.40) is worse than 87.85% of its industry peers.
Industry RankSector Rank
Current Ratio 1.4
Quick Ratio 1.4
AGTC Yearly Current Assets VS Current LiabilitesAGTC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 15.48% over the past year.
Looking at the last year, AGTC shows a very negative growth in Revenue. The Revenue has decreased by -35.00% in the last year.
The Revenue for AGTC have been decreasing by -61.71% on average. This is quite bad
EPS 1Y (TTM)15.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
Revenue 1Y (TTM)-35%
Revenue growth 3Y-80.17%
Revenue growth 5Y-61.71%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, AGTC will show a small growth in Earnings Per Share. The EPS will grow by 7.90% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y38.73%
EPS Next 2Y23.55%
EPS Next 3Y9.86%
EPS Next 5Y7.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AGTC Yearly Revenue VS EstimatesAGTC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5B 10B 15B
AGTC Yearly EPS VS EstimatesAGTC Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AGTC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AGTC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AGTC Price Earnings VS Forward Price EarningsAGTC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGTC Per share dataAGTC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.55%
EPS Next 3Y9.86%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGTC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

APPLIED GENETIC TECHNOLOGIES

NASDAQ:AGTC (11/30/2022, 8:18:22 PM)

After market: 0.3936 0 (0%)

0.3936

+0 (+1.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-21 2022-11-21/amc
Earnings (Next)02-13 2023-02-13
Inst Owners0.03%
Inst Owner Change0%
Ins Owners2.33%
Ins Owner Change0%
Market Cap26.62M
Analysts50
Price Target0.37 (-6%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-26.02%
Min EPS beat(2)-37.25%
Max EPS beat(2)-14.78%
EPS beat(4)0
Avg EPS beat(4)-24.61%
Min EPS beat(4)-37.25%
Max EPS beat(4)-14.78%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.41%
PT rev (3m)N/A
EPS NQ rev (1m)-8.82%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 81.91
P/FCF N/A
P/OCF N/A
P/B 1.51
P/tB 1.65
EV/EBITDA N/A
EPS(TTM)-1.42
EYN/A
EPS(NY)-0.73
Fwd EYN/A
FCF(TTM)-0.99
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0
BVpS0.26
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.39
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 86.05%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.4
Quick Ratio 1.4
Altman-Z -11.2
F-Score3
WACC11.71%
ROIC/WACCN/A
Cap/Depr(3y)93.46%
Cap/Depr(5y)69.78%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30%
EPS Next Y38.73%
EPS Next 2Y23.55%
EPS Next 3Y9.86%
EPS Next 5Y7.9%
Revenue 1Y (TTM)-35%
Revenue growth 3Y-80.17%
Revenue growth 5Y-61.71%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.96%
EBIT Next 3Y-3.21%
EBIT Next 5Y-0.71%
FCF growth 1Y-48.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.27%
OCF growth 3YN/A
OCF growth 5YN/A